Strategic Alliances
The CRO for CNS
Utilizing the worlds most sophisticated actigraphy recording device (AMI’s Motionlogger), Clinilabs is able to provide recording activity unobtrusively and objectively in studies of sleep, hyperactivity (ADHD) fatigue, circadian rhythm disorders, and other conditions. Featured in more peer-reviewed publication than any other activity monitor in the world, AMI’s Motionlogger provides additional measures of environmental light, temperature, and sound in ambulatory subjects. Our long-standing strategic alliance with Ambulatory Monitoring, Inc., allows Clinilabs to continue to provide advanced technology to streamline your clinical study.
Accelerating the development of new epilepsy therapeutic treatments to improve patient care is at the heart of The Epilepsy Study Consortium (TESC). Through their organizational goals of building partnerships between academia, industry, and regulatory agencies, Clinilabs is able to provide high-quality investigator sites for multicenter clinical trials. These efforts enable us to enroll adults and children with epilepsy and help bring new treatments to patients in need.
Without drugs, physicians would struggle to find relevance, and patients would suffer without hope.
The best way to predict the future is to invent it.
It is easy to get a thousand prescriptions, but hard to get one single remedy.
I am not accustomed to saying anything with certainty after only one or two observations.
The greatest joy in life is to accomplish. It is the getting, not the having. It is the giving, not the keeping.
I have no ideology. My ideology is health.
Remember the Three Princes of Serendip who went out looking for treasure? They didn’t find what they were looking for, but they kept finding things just as valuable. That’s serendipity, and our business [drugs] is full of it.
Good information is the best medicine.
If you think compliance is expensive, try non-compliance.
The cures we want aren’t going to fall from the sky. We have to get ladders and climb up and get them.
Drugs don’t work in patients who don’t take them.
Let me tell you the secret that has led me to my goal. My strength lies solely in my tenacity.
All truths are easy to understand once they are discovered; the point is to discover them.
One never notices what has been done; one can only see what remains to be done.
There is so much more to be done; the patients are waiting.
I must say, I spend a lot of my time these days trying to persuade people that controlled trials are the only way to get information that’s reliable about drugs.
The pace of discovery is going unbelievably fast.
Advances in drug development have led to greater improvement in the quality of human life than advances in all other fields combined.
The reward for work well done is the opportunity to do more.
I trust I may be enabled in the treatment of patients always to act with a single eye to their good.
One sometimes finds what one is not looking for.